Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 760943, 6 pages
http://dx.doi.org/10.1155/2014/760943
Research Article

Histological and Clinical Characteristics of Patients with Chronic Hepatitis C and Persistently Normal Alanine Aminotransferase Levels

1Department of Medicine, Section of Hepatology, University of Illinois at Chicago, 840 South Wood Street, Suite 130, Chicago, IL 60612, USA
2Department of Pathology (MC847), University of Illinois at Chicago, 840 South Wood Street, Suite 130, Chicago, IL 60612, USA

Received 4 March 2014; Revised 23 April 2014; Accepted 23 April 2014; Published 7 May 2014

Academic Editor: Annarosa Floreani

Copyright © 2014 Bakht Roshan and Grace Guzman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Pol, A. Vallet-Pichard, M. Corouge, and V. O. Mallet, “Hepatitis C: epidemiology, diagnosis, natural history and therapy,” Contributions to Nephrology, vol. 176, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Boyer and P. Marcellin, “Natural history of hepatitis C and the impact of anti-viral therapy,” Forum: Trends in Experimental and Clinical Medicine, vol. 10, no. 1, pp. 4–18, 2000. View at Google Scholar · View at Scopus
  3. D. Prati, E. Taioli, A. Zanella et al., “Updated definitions of healthy ranges for serum alanine aminotransferase levels,” Annals of Internal Medicine, vol. 137, no. 1, pp. 1–10, 2002. View at Google Scholar · View at Scopus
  4. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Zeuzem, M. Diago, E. Gane et al., “Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels,” Gastroenterology, vol. 127, no. 6, pp. 1724–1732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Puoti, L. Bellis, A. Galossi et al., “Antiviral treatment of HCV carriers with persistently normal ALT levels,” Mini-Reviews in Medicinal Chemistry, vol. 8, no. 2, pp. 150–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Persico, E. Persico, R. Suozzo et al., “Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels,” Gastroenterology, vol. 118, no. 4, pp. 760–764, 2000. View at Google Scholar · View at Scopus
  8. M. Martinot-Peignoux, N. Boyer, D. Cazals-Hatem et al., “Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA,” Hepatology, vol. 34, no. 5, pp. 1000–1005, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. L. Shiffman, M. Diago, A. Tran et al., “Chronic hepatitis C in patients with persistently normal alanine transaminase levels,” Clinical Gastroenterology and Hepatology, vol. 4, no. 5, pp. 645–652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mathurin, “Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity,” Hepatology, vol. 27, no. 3, pp. 868–872, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Marcellin, S. Levy, and S. Erlinger, “Therapy of hepatitis C: patients with normal aminotransferase levels,” Hepatology, vol. 26, supplement 1, no. 3, pp. 133S–136S, 1997. View at Google Scholar · View at Scopus
  13. N. C. Tassopoulos, “Treatment of patients with chronic hepatitis C and normal ALT levels,” Journal of Hepatology, vol. 31, supplement 1, pp. 193–196, 1999. View at Google Scholar · View at Scopus
  14. C. Puoti, L. Bellis, R. Guarisco, O. D. Unto, L. Spilabotti, and O. M. Costanza, “HCV carriers with normal alanine aminotransferase levels: healthy persons or severely ill patients? Dealing with an everyday clinical problem,” European Journal of Internal Medicine, vol. 21, no. 2, pp. 57–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Okanoue, M. Minami, A. Makiyama, Y. Sumida, K. Yasui, and Y. Itoh, “Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy,” Clinical Gastroenterology and Hepatology, vol. 3, supplement 2, pp. S89–S91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. F. M. Sanai, A. Helmy, C. Dale et al., “Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C,” Liver International, vol. 31, no. 7, pp. 1039–1046, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. G. Knodell, K. G. Ishak, and W. C. Black, “Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis,” Hepatology, vol. 1, no. 5, pp. 431–435, 1981. View at Google Scholar · View at Scopus
  18. L. B. Seeff, “The natural history of chronic hepatitis C virus infection,” Clinics in Liver Disease, vol. 1, no. 3, pp. 587–602, 1997. View at Google Scholar · View at Scopus
  19. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, supplement 1, no. 5, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Zapata, “Clinical aproach to the patient with chronic hepatitis C infection and normal aminotransferases,” Annals of Hepatology, vol. 9, no. 1, supplement, pp. 72–79, 2010. View at Google Scholar · View at Scopus
  21. S. C. Gordon, J. W. Fang, A. L. Silverman, J. G. McHutchison, and J. K. Albrecht, “The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C,” Hepatology, vol. 32, no. 2, pp. 400–404, 2000. View at Google Scholar · View at Scopus
  22. J. Jamal, “Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States,” Hepatology, vol. 30, no. 5, pp. 1307–1311, 2000. View at Google Scholar · View at Scopus
  23. C. Puoti, R. Castellacci, F. Montagnese et al., “Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC),” Journal of Hepatology, vol. 37, no. 1, pp. 117–123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Puoti, R. Guarisco, L. Bellis, and L. Spilabotti, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 50, no. 1, pp. 322–325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. N. N. Zein, J. Rakela, E. L. Krawitt, K. R. Reddy, T. Tominaga, and D. H. Persing, “Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy,” Annals of Internal Medicine, vol. 125, no. 8, pp. 634–639, 1996. View at Google Scholar · View at Scopus
  26. C. Puoti, R. Castellacci, and F. Montagnese, “Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?” Digestive and Liver Disease, vol. 32, no. 7, pp. 634–643, 2000. View at Google Scholar · View at Scopus
  27. C. Puoti, A. Magrini, T. Stati et al., “Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels,” Hepatology, vol. 26, no. 6, pp. 1393–1398, 1997. View at Google Scholar · View at Scopus
  28. S. Zeuzem, A. Alberti, W. Rosenberg et al., “Review article: management of patients with chronic hepatitis C virus infection and “normal” alanine aminotransferase activity,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 8, pp. 1133–1149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Dienstag and J. G. McHutchison, “American gastroenterological association medical position statement on the management of hepatitis C,” Gastroenterology, vol. 130, no. 1, pp. 225–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Puoti, “HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy,” Journal of Hepatology, vol. 38, no. 4, pp. 529–532, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, “Liver biopsy,” Hepatology, vol. 49, no. 3, pp. 1017–1044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Puoti, R. Guarisco, L. Spilabotti et al., “Should we treat HCV carriers with normal ALT levels? the “5Ws” dilemma,” Journal of Viral Hepatitis, vol. 19, no. 4, pp. 229–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S.-N. Lu, J.-H. Wang, S.-L. Liu et al., “Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma,” Cancer, vol. 107, no. 9, pp. 2212–2222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. H. A. Azevedo, C. A. Villela-Nogueira, R. M. Perez et al., “Similar HCV viral load levels and genotype distribution among end-stage renal disease patients on hemodialysis and HCV-infected patients with normal renal function,” Journal of Nephrology, vol. 20, no. 5, pp. 609–616, 2007. View at Google Scholar · View at Scopus
  35. A. M. Contreras, I. Ruiz, G. Polanco-Cruz et al., “End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage,” Annals of Hepatology, vol. 6, no. 1, pp. 48–54, 2007. View at Google Scholar · View at Scopus
  36. M. R. Hassan, N. R. N. Mustapha, F. M. Zawawi, B. S. P. Earnest, K. Voralu, and S. P. Pani, “A comparison of genotype and markers of disease severity of chronic hepatitis C in patients with and without end-stage renal disease,” Singapore Medical Journal, vol. 52, no. 2, pp. 86–89, 2011. View at Google Scholar · View at Scopus